Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis by Mease, Philip J et al.
Vol.:(0123456789) 
Rheumatology International 
https://doi.org/10.1007/s00296-020-04564-x
CLINICAL TRIALS
Poor prognostic factors in predicting abatacept response in a phase III 
randomized controlled trial in psoriatic arthritis
Philip J. Mease1,7  · Iain B. McInnes2 · Vibeke Strand3 · Oliver FitzGerald4 · Harris A. Ahmad5 · Yedid Elbez6 · 
Subhashis Banerjee5
Received: 8 October 2019 / Accepted: 23 March 2020 
© The Author(s) 2020
Abstract
In ASTRAEA (NCT01860976), abatacept significantly increased American College of Rheumatology criteria 20% (ACR20) 
responses at Week 24 versus placebo in patients with psoriatic arthritis (PsA). This post hoc analysis explored relationships 
between prospectively identified baseline characteristics [poor prognostic factors (PPFs) ] and response to abatacept. Patients 
were randomized (1:1) to receive subcutaneous abatacept 125 mg weekly or placebo for 24 weeks; those without ≥ 20% 
improvement in joint counts at Week 16 switched to open-label abatacept. Potential predictors of ACR20 response were 
identified by treatment arm using multivariate analyses. Likelihood of ACR20 response to abatacept versus placebo was 
compared in univariate and multivariate analyses in subgroups stratified by the PPF, as defined by EULAR and/or GRAPPA 
treatment guidelines. Odds ratios (ORs) were generated using logistic regression to identify meaningful differences (OR 
cut-off: 1.2). 424 patients were randomized and treated (abatacept n = 213; placebo n = 211). In abatacept-treated patients, 
elevated C-reactive protein (CRP), high Disease Activity Score based on 28 joints (CRP), presence of dactylitis, and ≥ 3 
joint erosions were identified as predictors of response (OR > 1.2). In placebo-treated patients, only dactylitis was a potential 
predictor of response. In the univariate analysis stratified by PPF, ACR20 response was more likely (OR > 1.2) with abatacept 
versus placebo in patients with baseline PPFs than in those without; multivariate analysis confirmed this finding. Response to 
abatacept versus placebo is more likely in patients with features indicative of high disease activity and progressive disease; 
these characteristics are recognized as PPFs in treatment guidelines for PsA.
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Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory disease, 
with a range of skin and musculoskeletal manifestations 
[1]. Although various treatments for PsA are now available, 
a substantial number of patients do not benefit adequately 
from them and, as such, an unmet medical need remains [2, 
3]. In addition to the availability of new agents with novel 
modes of action, patients would also benefit from improved 
clinical decision making using predictive factors for 
response to existing agents currently used in routine practice.
Abatacept, a selective T-cell co-stimulation modulator 
with a distinct mechanism of action upstream of other cur-
rently available agents [4], is approved for the treatment of 
rheumatoid arthritis (RA), juvenile idiopathic arthritis, and 
active PsA in adults [5]. In the phase III Active pSoriaTic 
aRthritis rAndomizEd triAl (ASTRAEA, NCT01860976), 
treatment with subcutaneous (SC) abatacept 125 mg weekly 
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resulted in a significantly higher proportion of patients with 
active PsA achieving ≥ 20% improvement in the American 
College of Rheumatology criteria (ACR20) versus placebo 
at Week 24 (primary endpoint; abatacept: 39.4%, placebo: 
22.3%). Benefits of abatacept treatment based on ACR20 
responses were observed regardless of prior tumour necro-
sis factor inhibitor (TNFi) exposure; however, such ben-
efits were more pronounced in TNFi-naïve versus -exposed 
patients (TNFi-naïve patients: abatacept: 44.0%, placebo 
22.2%; TNFi-exposed patients: abatacept: 36.4%, placebo 
22.3%) [6]. In addition, abatacept reduced structural dam-
age, alleviated musculoskeletal symptoms including enthesi-
tis and dactylitis, and modestly improved psoriatic skin man-
ifestations (proportions of patients with ≥ 75% improvement 
in Psoriasis Area and Severity Index score from baseline at 
Week 24: abatacept 16.4%, placebo 10.1%), with no new 
safety concerns [6]. Further investigations were conducted 
to identify specific patient subpopulations who were most 
likely to respond to abatacept treatment.
The latest European League Against Rheumatism 
(EULAR) PsA treatment guidelines consider the following 
factors to be indicative of poor or adverse prognosis: ≥ 5 
active joints, radiographic damage, elevated acute-phase 
reactants, and extra-articular manifestations, particularly 
dactylitis [7]. ACR/National Psoriasis Foundation treat-
ment guidelines, the EULAR treatment recommendations, 
and PsA treatment guidelines issued by the Group for 
Research and Assessment of Psoriasis and Psoriatic Arthritis 
(GRAPPA) recognize that the aforementioned poor prog-
nostic factors (PPFs) could determine the need to initiate 
biologic disease-modifying antirheumatic drug (bDMARD) 
treatment in patients with an inadequate response or intoler-
ance to methotrexate (MTX) [7, 8]. Specific clinical char-
acteristics or biomarkers that enable clinicians to make an 
informed decision on the choice of individualized bDMARD 
treatment are currently lacking, and PPFs could be useful in 
this regard, as shown previously for patients with rheumatoid 
arthritis (RA) [10–12]. The aim of this post hoc analysis of 
ASTRAEA was to evaluate the relationship between pro-
spectively identified baseline characteristics, particularly 
those indicative of poor prognosis, and response to abatacept 
treatment in patients with active PsA.
Materials and methods
Study design, patient population, and treatment
The design, eligibility criteria, and main study endpoints of 
this multicenter, phase III, randomized controlled trial have 
been described previously [6]. Briefly, eligible patients were 
randomized (1:1) to receive SC abatacept 125 mg weekly 
or placebo for 24 weeks, followed by an open-label period, 
during which patients received SC abatacept for 28 weeks 
(total study period of 52 weeks). Patients without ≥ 20% 
improvement in tender (TJC) and swollen (SJC) joint 
counts at Week 16 were switched to open-label abatacept 
for 28 weeks (early escape, total study period of 44 weeks). 
Key eligibility criteria included age ≥ 18 years, PsA diag-
nosis per the Classification Criteria for PsA (CASPAR) 
[13], active arthritis (defined as ≥ 3 tender and ≥ 3 swollen 
joints), active plaque psoriasis with ≥ 1 qualifying target 
lesion ≥ 2 cm in diameter, and inadequate response or intol-
erance to ≥ 1 non-biologic DMARD. Both TNFi-naïve and 
-exposed patients were included and stratification by prior 
TNFi exposure was implemented. The primary endpoint 
was the proportion of patients with an ACR20 response at 
Week 24. A key secondary endpoint was Week 24 ACR20 
response rate in TNFi-naïve and -exposed subgroups.
Baseline characteristics and poor prognostic factors
In this post hoc analysis, several baseline characteristics 
that are recognized PPFs in EULAR and/or GRAPPA rec-
ommendations for PsA [7, 8] were investigated as poten-
tial predictors of ACR20 response. The following variables 
were included in the analyses: elevated C-reactive pro-
tein (CRP) using the cut-off of the upper limit of normal 
(ULN; 3 mg/L); the presence of joint erosions using a cut-
off based on the median baseline number of radiographic 
erosions (PsA-modified Sharp/van der Heijde score) in the 
total study population [the median baseline value was 2.5, 
rounded to 3 for the cut-off in this analysis (i.e., ≥ vs < 3)]; 
the presence of extra-articular manifestations recognised as 
PPFs (such as dactylitis or enthesitis); and Disease Activity 
Score based on 28 joints [DAS28 (CRP)] indicating high 
disease activity/severe joint disease using a cut-off of 5.1, 
as described for RA [14, 15]. Baseline characteristics were 
compared descriptively between abatacept- and placebo-
treated patients in the overall study population and the TNFi-
naïve and -exposed subgroups.
Identification of predictors of response
Univariate and multivariate analyses were performed to 
identify potential factors that influenced ACR20 treatment 
response. Odds ratios (ORs) and 95% confidence intervals 
(CIs) were calculated based on a logistic regression model 
to determine differences in ACR20 responses. A cut-off of 
1.2 was used to identify meaningful differences.
Multivariate analyses were performed on data from 
individual treatment arms to identify potential predictors 
of response within each treatment group. Subsequently, 
univariate analyses were performed to identify patient sub-
groups, according to the presence or absence of previously 
defined PPFs at baseline, in whom abatacept appeared to 
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have a meaningful treatment benefit over placebo. Those 
PPFs with an OR cut-off ≥ 1.2 were investigated in more 
detail through multivariate analyses stratified by the defined 
PPFs. Covariates employed for the full multivariate model 
adjustment included: treatment arm, prior TNFi exposure 
(yes/no), concomitant MTX use (yes/no), baseline CRP 
(≤ or > ULN), baseline joint erosion (< or ≥ 3), baseline 
DAS28 (CRP) (≤ or > 5.1), baseline dactylitis (yes/no), 
baseline enthesitis (yes/no), and baseline Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) (< or ≥ 4). 
Analyses were performed to identify predictors of response 
in the whole study population and also in the subgroups of 
TNFi-naïve and -exposed patients.
Patient consent and ethics approval
The study was conducted in accordance with the Declara-
tion of Helsinki, International Conference on Harmonisation 
Guidelines for Good Clinical Practice, and local regulations. 
An Institutional Review Board or Independent Ethics Com-
mittee approved the protocol, consent form, and any other 
written information provided to patients. Patients were eval-
uated by the investigators, and the data were collected and 
analysed by Bristol-Myers Squibb under the direction of the 
investigators [6].
Results
Patients
Of 424 randomized patients, 213 and 211 received at least 1 
dose of abatacept and placebo, respectively. Detailed analy-
sis of baseline characteristics has been reported previously 
[6]. Briefly, the overall mean [standard deviation (SD)] age 
was 50.4 (11.0) years, 55% of patients were female, and 60% 
Table 1  Selected baseline characteristics of patients in ASTRAEA
Data are n (%) calculated based on the total number of patients with available data for each characteristic unless otherwise indicated
Baseline is study Day 1
ASTRAEA Active pSoriaTic aRthritis rAndomizEd trial, CRP C-reactive protein, SC subcutaneous, TNFi tumor necrosis factor inhibitor, ULN 
upper limit of normal (3 mg/L)
a Median (minimum, maximum) erosion score in the abatacept group was 2.0 (0, 203), in the placebo group was 2.8 (0, 149), and in total popula-
tion was 2.5 (0, 203)
Abatacept (n = 213) Placebo (n = 211) Overall (N = 424)
Overall population Erosion  scorea > 0 173 (84.4) 168 (83.2) 341 (83.8)
≤ 0 32 (15.6) 34 (16.8) 66 (16.2)
≥ 3 91 (44.2) 88 (43.6) 179 (43.9)
< 3 115 (55.8) 114 (56.4) 229 (56.1)
CRP > ULN 146 (68.9) 131 (62.7) 277 (65.8)
≤ ULN 66 (31.1) 78 (37.3) 144 (34.2)
Tender and swollen joints Tender ≥ 5 or swollen ≥ 5 209 (98.1) 207 (98.1) 416 (98.1)
Tender < 5 and swollen < 5 4 (1.9) 4 (1.9) 8 (1.9)
TNFi-naïve Erosion  scorea > 0 71 (86.6) 65 (85.5) 136 (86.1)
≤ 0 11 (13.4) 11 (14.5) 22 (13.9)
≥ 3 28 (33.3) 19 (23.5) 47 (28.5)
< 3 56 (66.7) 62 (76.5) 118 (71.5)
CRP > ULN 54 (65.1) 46 (58.2) 100 (61.7)
≤ ULN 29 (34.9) 33 (41.8) 62 (38.3)
Tender and swollen joints Tender ≥ 5 or swollen ≥ 5 83 (98.8) 79 (97.5) 162 (98.2)
Tender < 5 and swollen < 5 1 (1.2) 2 (2.5) 3 (1.8)
TNFi-exposed Erosion  scorea > 0 102 (82.9) 103 (81.7) 205 (82.3)
≤ 0 21 (17.1) 23 (18.3) 44 (17.7)
≥ 3 36 (27.9) 45 (34.6) 81 (31.3)
< 3 93 (72.1) 85 (65.4) 178 (68.7)
CRP  > ULN 92 (71.3) 85 (65.4) 177 (68.3)
≤ ULN 37 (28.7) 45 (34.6) 82 (31.7)
Tender and swollen joints Tender ≥ 5 or swollen ≥ 5 126 (97.7) 128 (98.5) 254 (98.1)
Tender < 5 and swollen < 5 3 (2.3) 2 (1.5) 5 (1.9)
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reported current MTX use at baseline. Approximately 60% 
of patients had been previously exposed to TNFis. Selected 
baseline characteristics for the overall population and TNFi-
naïve and -exposed subgroups are presented in Table 1. 
Baseline joint erosion score, CRP, and the proportions of 
patients with ≥ 5 TJC or SJC were balanced between treat-
ment arms.
Predictors of response to abatacept in the overall 
population
Several PPFs were identified as potential predictors of 
response in univariate and multivariate analyses by treatment 
arm. Among patients treated with abatacept, numerically 
higher ACR20 response rates (OR > 1.2) were seen between 
subgroups of patients stratified by higher median base-
line joint erosions [≥ 3 vs < 3; OR (95% CI) 1.924 (1.032, 
3.587)], elevated baseline CRP levels [> ULN vs ≤ ULN; OR 
(95% CI) 1.346 (0.668, 2.712)], high DAS28 (CRP) [> 5.1 
vs ≤ 5.1; OR (95% CI) 1.489 (0.782, 2.836)], and presence 
of dactylitis [yes vs no; OR (95% CI) 1.372 (0.708, 2.659)]. 
In patients receiving placebo, only dactylitis (presence vs 
absence) was found to numerically discriminate ACR20 
responses between subgroups [OR (95% CI) 1.406 (0.619, 
3.193)].
In the univariate analysis stratified by PPFs, a signifi-
cant benefit of abatacept versus placebo with regard to 
achievement of an ACR20 response (defined as OR > 1.2 
with 95% CIs that did not cross 1; p < 0.05) was evident in 
all subgroups of patients with the defined PPFs at baseline 
(Fig. 1). A significant but lesser benefit of abatacept was 
also observed in subgroups of patients without these PPFs 
at baseline, i.e., those without high disease activity [DAS28 
(CRP) ≤ 5.1] and with no enthesitis.
The multivariate model in which patients were stratified 
by PPFs confirmed significant benefits with abatacept versus 
placebo for ACR20 responses (95% CIs of OR did not cross 
1; p < 0.05) in the subgroups of patients positive for each of 
the defined PPFs at baseline. As in the univariate analysis, 
no significant treatment benefits (i.e., 95% CI crossing 1 for 
OR) were seen for patients without PPFs at baseline, with 
the exception of the absence of dactylitis (Fig. 2).
Predictors of response to abatacept in TNFi‑naïve 
and ‑exposed subgroups
In TNFi-naïve patients, significant benefits of abatacept 
treatment versus placebo in terms of ACR20 response rates 
(p < 0.05) were evident in patients with baseline CRP > ULN 
or joint erosion score ≥ 3. However, there was no clear 
Fig. 1  Univariate analysis of ACR20 response rate by poor prognos-
tic factors (overall population). *p < 0.05. ACR20 American College 
of Rheumatology criteria 20% improvement, CI confidence interval, 
CRP C-reactive protein; DAS28 Disease Activity Score based on 28 
joints, ULN upper limit of normal (3 mg/L)
Rheumatology International 
1 3
association of response with presence or absence of other 
PPFs. The benefit of abatacept was numerically higher com-
pared with placebo regardless of the presence or absence of 
each specific PPF at baseline (Fig. 3).
In TNFi-exposed patients, a significant (p < 0.05) ben-
efit of abatacept compared with placebo was seen in most 
subgroups of patients with the defined PPFs at baseline: 
CRP > ULN, joint erosion score ≥ 3, and presence of dacty-
litis or enthesitis (Fig. 4).
Discussion
The analyses reported here defined certain baseline disease 
characteristics that could be used in clinical practice to iden-
tify patients with PsA in whom abatacept may be particu-
larly effective. Notably, these characteristics were consistent 
with known PPFs in PsA.
Significant unmet needs remain in PsA, and treatment rec-
ommendations emphasize the importance of further research 
to determine predictive factors of treatment response with 
specific therapeutic agents [7]. The EULAR guidelines on 
the management of PsA recommend to initiate treatment 
with bDMARDs if the presence of PPFs is determined [7]. If 
PPFs were also predictive of enhanced response to biologic 
therapies, then their presence could be seen as another rea-
son to initiate these treatments early. In patients with active 
RA, the presence of PPFs at baseline, including autoantibod-
ies and early joint erosions, has been associated with greater 
treatment benefits [14, 16, 17]. Our findings indicate that, as 
in RA, baseline disease characteristics associated with poor 
prognosis may also identify patients with PsA who are more 
likely to respond to abatacept.
Baseline characteristics of the ASTRAEA study popula-
tion have been reported in detail previously [6] and indicate 
a population with generally difficult-to-treat PsA with an 
aggressive disease course. Notably, most patients had been 
exposed to TNFi agents, and most had failed at least 1 TNFi 
due to an inadequate response. In addition, radiographic 
joint erosions were present in 84% of patients, 66% had ele-
vated CRP (> ULN), with a mean (SD) level of 14.1 (25.9) 
mg/L, and nearly all patients (98%) had a polyarticular 
Fig. 2  Multivariate analysis of ACR20 response rate by poor prog-
nostic factors (overall population). *p < 0.05. Covariates employed 
in the full model included: treatment arm, prior TNFi exposure, 
concomitant methotrexate use, baseline CRP (≤ or > ULN), baseline 
DAS28 (CRP) (≤ or > 5.1), baseline enthesitis (yes/no), baseline dac-
tylitis (yes/no), baseline erosion (median < or ≥ 3), and baseline BAS-
DAI category (< or ≥ 4). In the reduced model, a stepwise algorithm 
was used. A significance level of 0.3 was required to allow a vari-
able to be included in the model and a significance level of 0.2 was 
required for a variable to stay in the model. ACR20 American College 
of Rheumatology criteria 20% improvement, BASDAI Bath Ankylos-
ing Spondylitis Disease Activity Index, CI confidence interval, CRP 
C-reactive protein, DAS28 Disease Activity Score based on 28 joints, 
TNFi tumor necrosis factor inhibitor, ULN upper limit of normal 
(3 mg/L)
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disease, with mean (SD) TJC of 20.2 (13.3) and SJC of 11.6 
(7.5) [6]. In patients with disease features indicative of a 
poor prognosis and a history of treatment failure, informa-
tion to guide treatment options would be particularly useful 
to improve long-term outcomes.
In this analysis, baseline characteristics recognized in 
EULAR and GRAPPA guidelines as PPFs in PsA (joint ero-
sion score, CRP level, extra-articular manifestations such 
as enthesitis and dactylitis, and level of disease activity; 
Table 2) [7, 8] were prospectively identified and investigated 
for their potential to predict response to abatacept in a popu-
lation of patients with active disease. Our results showed that 
these recognized PPFs could identify a subgroup of patients 
most likely to have the highest response to abatacept. The 
findings of the univariate analysis showed that the presence 
of the above PPFs at baseline was associated with a signifi-
cantly higher likelihood of ACR20 response versus placebo. 
The multivariate model supported the results observed in 
the univariate analysis and further indicated a greater treat-
ment effect with abatacept versus placebo in patients with 
PPFs. Elevated CRP (> ULN), high disease activity [DAS28 
(CRP) > 5.1], presence of enthesitis, and baseline joint ero-
sion score ≥ 3 were all associated with statistically signifi-
cant abatacept treatment benefit versus placebo. Notably, 
when stratified by prior TNFi use, absence of enthesitis or 
dactylitis was a better predictor of response than the pres-
ence of these PPFs in the TNFi-naive subgroup; this could 
be attributed to a certain degree of variability in the findings 
due to a small sample size.
A number of limitations of this analysis should be 
considered. First, these analyses were post hoc in nature, 
allowing for potential statistical bias. Second, only a lim-
ited number of baseline factors were examined (based on 
the ACR, EULAR and GRAPPA recommendations [7–9]) 
and as such, other important PPFs or baseline disease and 
patient characteristics that predict response specifically in 
peripheral joints may have been overlooked. In addition, a 
limited number of significant predictors were identified in 
the multivariate analysis due to the high number of con-
founding variables, thus limiting the findings. Finally, the 
variable findings for the TNFi subgroups (TNFi-naïve and 
TNFi-exposed) may be limited by low numbers in each 
subpopulation.
In conclusion, this analysis demonstrated that abatacept 
is most likely to be effective in patients with PsA who 
have disease characteristics indicative of poor prognosis, 
such as elevated CRP, high disease activity, and erosive 
disease at treatment initiation. These findings should assist 
clinicians in making informed decisions regarding the use 
of abatacept in the treatment of patients with active PsA.
Fig. 3  Univariate analysis of ACR20 response rate by poor prognostic 
factors (TNFi-naïve population). *p < 0.05. ACR20 American College 
of Rheumatology criteria 20% improvement, CI confidence interval, 
CRP C-reactive protein, DAS28 Disease Activity Score based on 28 
joints, ULN upper limit of normal (3 mg/L)
Rheumatology International 
1 3
Acknowledgements The authors would like to thank June Ye at 
Bristol-Myers Squibb for providing help with statistical analysis. Pro-
fessional medical writing and editorial assistance was provided by 
Katerina Kumpan, PhD, at Caudex and was funded by Bristol-Myers 
Squibb.
Author contributions All authors contributed to the study conception 
and design and interpretation of data. PJM and HAA contributed to 
the acquisition of data. All authors contributed to drafting the article 
or revising it critically for important intellectual content. All authors 
approved the version of this article to be published. The first draft of 
the manuscript was written by Katerina Kumpan, PhD, at Caudex, 
under the direction from all authors, and all authors commented on all 
versions of the manuscript.
Funding This study was funded by Bristol-Myers Squibb.
Data sharing statement Bristol-Myers Squibb’s policy on data sharing 
may be found at https ://www.bms.com/resea rcher s-and-partn ers/clini 
cal-trial s-and-resea rch/discl osure -commi tment .html.
Compliance with ethical standards 
Conflict of interest PJM reports receiving grant support from AbbVie, 
Amgen, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Novartis, 
Pfizer, Sun, and UCB; consulting fees from AbbVie, Amgen, Bristol-
Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, 
Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and speaker fees from 
AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Jans-
sen, Lilly, Novartis, Pfizer, and UCB. IBM reports receiving research 
grants from Bristol-Myers Squibb, Celgene, Janssen, Novartis, and 
UCB; and consulting fees from AbbVie, Bristol-Myers Squibb, Cel-
gene, Janssen, Novartis, and UCB. VS reports receiving consulting 
Fig. 4  Univariate analysis of ACR20 response rate by poor prognos-
tic factors (TNFi-exposed population). *p < 0.05. ACR20 American 
College of Rheumatology criteria 20% improvement, CI confidence 
interval, CRP C-reactive protein, DAS28 Disease Activity Score 
based on 28 joints, ULN upper limit of normal (3 mg/L)
Table 2  EULAR and GRAPPA 
recommendations for defining 
adverse/poor prognostic factors 
in PsA [7, 8, 15–20]
EULAR European League Against Rheumatism, GRAPPA Group for Research and Assessment of Psoriasis 
and Psoriatic Arthritis, PsA psoriatic arthritis
EULAR [7] GRAPPA [8]
“Elevated acute phase reactants” “Increased levels of 
inflammatory markers”
“Radiographic damage (joint destruction)”
“High number of actively involved joints either tender or swollen (defined as 
5 or more)”
“High active joints counts”
“Extra-articular manifestation, in particular dactylitis”
 Rheumatology International
1 3
fees from AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingel-
heim, Bristol-Myers Squibb, Celltrion, Corrona, Crescendo, Genen-
tech/Roche, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, 
Regeneron, Samsung, Sandoz, Sanofi, and UCB. OF reports receiving 
research grants from Bristol-Myers Squibb. HAA and SB are employ-
ees of Bristol-Myers Squibb and report holding stock in Bristol-Myers 
Squibb. YE is consultant for Bristol-Myers Squibb.
Ethical standards Schulman Associates Institutional Review Board or 
Independent Ethics Committees approved the protocol, consent form, 
and any other written information provided to patients or their legal 
representatives.
Patient consent All patients gave written informed consent prior to 
study entry.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) 
Psoriatic arthritis: epidemiology, clinical features, course, and 
outcome. Ann Rheum Dis. 64(Suppl 2):ii14–ii17
 2. FitzGerald O, Winchester R (2009) Psoriatic arthritis: from patho-
genesis to therapy. Arthritis Res Ther 11(1):214
 3. Ramiro S, Smolen JS, Landewe R, van der Heijde D, Dougados 
M, Emery P et al (2016) Pharmacological treatment of psoriatic 
arthritis: a systematic literature review for the 2015 update of 
the EULAR recommendations for the management of psoriatic 
arthritis. Ann Rheum Dis 75(3):490–498
 4. Cutolo M, Nadler S (2013) Advances in CTLA-4-Ig-mediated 
modulation of inflammatory cell and immune response activation 
in rheumatoid arthritis. Autoimmun Rev 12(7):758–767
 5. Orencia prescribing information. 2017. https ://packa geins erts.bms.
com/pi/pi_orenc ia.pdf. Accessed 2 Feb 2018.
 6. Mease PJ, Gottlieb AB, van der Heijde D, FitzGerald O, Johnsen A, 
Nys M et al (2017) Efficacy and safety of abatacept, a T-cell modu-
lator, in a randomised, double-blind, placebo-controlled, phase III 
study in psoriatic arthritis. Ann Rheum Dis 76:1550–1558
 7. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M 
et al (2016) European League Against Rheumatism (EULAR) rec-
ommendations for the management of psoriatic arthritis with phar-
macological therapies: 2015 update. Ann Rheum Dis 75(3):499–510
 8. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-
Felquer M, Armstrong AW et al (2016) Group for research and 
assessment of psoriasis and psoriatic arthritis 2015 treatment 
recommendations for psoriatic arthritis. Arthritis Rheumatol 
68(5):1060–1071
 9. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A 
et al (2019) Special article: 2018 American College of Rheumatol-
ogy/National Psoriasis Foundation guideline for the treatment of 
psoriatic arthritis. Arthritis Care Res (Hoboken) 71(1):2–29
 10. Alemao E, Postema R, Elbez Y, Mamane C, Finckh A (2019) Pres-
ence of anti-cyclic citrullinated peptide antibodies is associated with 
better treatment response to abatacept but not to TNF inhibitors 
in patients with rheumatoid arthritis: a meta-analysis. Clin Exp 
Rheumatol
 11. Endo Y, Koga T, Kawashiri SY, Morimoto S, Nishino A, Okamoto 
M et al (2020) Anti-citrullinated protein antibody titre as a predic-
tor of abatacept treatment persistence in patients with rheumatoid 
arthritis: a prospective cohort study in Japan. Scand J Rheumatol 
49(1):13–17
 12. Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, 
Johnsen A et al (2016) Impact of baseline anti-cyclic citrullinated 
peptide-2 antibody concentration on efficacy outcomes following 
treatment with subcutaneous abatacept or adalimumab: 2-year 
results from the AMPLE trial. Ann Rheum Dis 75(4):709–714
 13. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, 
Mielants H (2006) Classification criteria for psoriatic arthritis: 
development of new criteria from a large international study. Arthri-
tis Rheum 54(8):2665–2673
 14. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou 
K, Dougados M et al (2017) EULAR recommendations for the 
management of rheumatoid arthritis with synthetic and biological 
disease-modifying antirheumatic drugs: 2016 update. Ann Rheum 
Dis 76(6):960–977
 15. Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Key-
stone E et al (2009) Radiographic changes in rheumatoid arthritis 
patients attaining different disease activity states with methotrex-
ate monotherapy and infliximab plus methotrexate: the impacts of 
remission and tumour necrosis factor blockade. Ann Rheum Dis 
68(6):823–827
 16. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt 
J, Durez P et al (2009) Clinical efficacy and safety of abatacept in 
methotrexate-naive patients with early rheumatoid arthritis and poor 
prognostic factors. Ann Rheum Dis 68(12):1870–1877
 17. Bathon J, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez 
P et al (2011) Sustained disease remission and inhibition of radio-
graphic progression in methotrexate-naive patients with rheumatoid 
arthritis and poor prognostic factors treated with abatacept: 2-year 
outcomes. Ann Rheum Dis 70(11):1949–1956
 18. Brockbank JE, Stein M, Schentag CT, Gladman DD (2005) Dac-
tylitis in psoriatic arthritis: a marker for disease severity? Ann 
Rheum Dis 64(2):188–190
 19. Simon P, Pfoehler C, Bergner R, Schreiber M, Pfreundschuh M, 
Assmann G (2012) Swollen joint count in psoriatic arthritis is 
associated with progressive radiological damage in hands and feet. 
Clin Exp Rheumatol 30(1):45–50
 20. Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso 
EH (2010) Risk factors for radiographic progression in psoriatic 
arthritis: subanalysis of the randomized controlled trial ADEPT. 
Arthritis Res Ther 12(3):R113
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
